Recent

% | $
Quotes you view appear here for quick access.

Omeros Corporation (OMER) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rrtzrealmd rrtzrealmd Jan 15, 2013 10:02 AM Flag

    Why should I buy OMER now?

    ...why long????...seriously?...wouldn't "why short" be a more intelligent queation?...

    ...well, let's see...first, they're trying to develop a product that nobody wants -- i.e. a witches brew of ingredients to be used as an irrigation fluid -- because there are either drugs already available that accomplish the same alleged goals at likely much cheaper prices...

    ...second, the "witches brew" so far has not even demonstrated that it's particularly effective at doing what it claims -- as demonstrated by the phase 3 failures...

    ...third, a recent 8k announced the company intends to sell 60 MILLION DOLLARS worth of its stock...not only that, but it claims the right to sell this stock ANY time it pleases and at ANY price it desires...think in terms of a large sharp object hanging over the stock price ready to fall at management's whim...

    ...fourth, another recent 8k announced that the company has ADDED to their debt load and now has borrowed 20 MILLION dollars on which they pay 9.25% and which carries a prepayment penalty to boot!...

    ...hoo boy!...the only thing that'll salvage this company's stock is a good PR firm!...but in the wonderful world of biotech, that's mostly what it's all about anyway, right?...HAW, HAW, HAW!!!...

    Sentiment: Strong Sell

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Wow - I've never seen such enthusiasm over ignorant comments. Phase III "failures" - of the three phase III trials the company has completed, the two lens replacement trials have had over-the-top positive results and the knee surgery trial had mixed results. Please provide us with the competing drugs that are cheaper and more effective than the company's "witches brew" - you don't even know the pricing that the lens replacement drug will be, but you know that there are cheaper drugs? If having a shelf registration in place was the reason to sell/avoid a company's stock, then not many small-cap biotechs, who are always needing to raise money, would be worth buying. The debt raise is a good thing - obviously the lender is looking at the lens replacement trial/pending NDA & launch as reason to advance additional funds - again, most small cap biotechs would love to be able to borrow money at 9.25%, instead of pushing further dilution on their shareholders, but for you it is a negative - just proves your ignorance!

      • 1 Reply to tredleon
      • ..."wow" -- per Omeros' press releases:

        "Each of the APIs in OMS103HP are components of generic, FDA-approved drugs that have been marketed in the United States as over-the-counter or prescription drug products for over 15 years and have established and well-characterized safety profiles."

        ...those three drugs in the joint solution are Afrin, Orudis, and Elavil...in the eye solution they are Orudis and phenylephrine...all of them have REAL CHEAP generic alternatives that are more easily administered than an irrigating solution...

        ...OMER would try to argue, per the patent:

        "It is impossible to obtain an equivalent therapeutic effect by delivering similarly dosed agents via systemic (e.g., intravenous, subcutaneous, intramuscular or oral) routes of drug administration since drugs given systemically are subject to first- and second-pass metabolism."

        ...that is pure unadulterated baloney -- I would have preferred a stronger word but prissy Yahoo would censor me if I did...

        ...OMER offers absolutely no evidence to support any claim that "irrigating" with their solution produces a higher and/or more effective local concentration than can be achieved by IV or oral dosing...

        ...in FACT, oral or IV administration probably would be MORE effective since once an irrigation stops, then those drugs' effects should dissipate quickly while the oral/IV will persist...

        ...as regards the mydriatics, there are a half dozen or so generic eyedrops available that work every bit as well as any irrigating solution -- what do you think they use currently in ophthalmological surgery?...

        ...in order to prove superiority, OMER would have to do trials comparing using its solutions to using orally or IV administered drugs and drugs currently in use...but they haven't been doing that now, have they?...

        ...why not?...because they already know that their "witches' brew" would fail...

        ...the only two things OMER's solutions have are "jack" and -- oops -- Yahoo's censor says you have to guess the other one...HAW, HAW, HAW!!!!...

        Sentiment: Strong Sell

 
OMER
21.20-0.02(-0.09%)May 22 4:00 PMEDT